Condition: Neuropathic Pain · PTSD · Sponsor: Margaux M. Salas, PhD
This study is aimed to evaluate outpatient ketamine infusion within a military chronic neuropathic pain population and its effect on PTSD. Currently, this is a pilot study with 30 participants. Participants will be randomized to (1) a moderate dose ketamine, (2) moderate dose ketamine +Mg, or (3) a magnesium control group. Participants will complete self-reported pain and PTSD questionnaires throughout the \~24-week study period. The outlined strategy will provide evidence for the utility of ketamine in neuropathic pain management and pain associated comorbidities within a military population.
This description comes directly from the study's public registry record.
Margaux M Salas, PhD · 210-473-7447 · margaux.m.salas.ctr@health.mil
Kevin C Peterson, MD · 210-916-7331 · kevin.c.peterson3.mil@health.mil
Always discuss trial participation with your own doctor first.
| Brooke Army Medical Center | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06414356